Award-winning actor and producer Sterling K. Brown joins Bristol-Myers Squibb in effort to share stories of What It's Like to Live with Cancer Today

Bristol-Myers SquibbTwo-time Emmy Award winner Sterling K. Brown (This Is Us, Black Panther) is partnering with Bristol-Myers Squibb on a series designed to illuminate the triumphs and challenges of life after a cancer diagnosis. Survivorship Today: What It's Like to Live with Cancer explores the stories of people who have experienced lasting physical, emotional and social effects from cancer to build greater understanding of, and draw attention to, survivorship-related issues.

Today, more people who have been diagnosed with cancer are able to live with the disease than ever before. During this time of rapid progress in cancer treatment, researchers are only just beginning to understand the long-term impacts of the disease on individuals and their loved ones. As the number of cancer survivors in the United States (U.S.) grows to nearly 17 million this year, it is increasingly important to recognize and address the current realities of cancer survivorship. Brown, who lost his uncle to cancer, is speaking with people around the country who have been impacted by the disease to find out what it's like to live with cancer today.

"When my uncle, Sonny, passed away from cancer just six months after his diagnosis, my entire family was devastated. Now, 15 years later, many people with cancer are living longer," said Brown. "While that means they might have a chance to celebrate another birthday or watch their children have children, it also means their lives have likely been forever changed. Survivorship Today will bring these experiences to light to show the long-term effects of cancer, with the goal of helping people feel supported every step of their journey."

Through the stories of people affected by cancer, the series will delve into topics such as:

  • Overcoming barriers: Some people who are diagnosed with cancer face a greater burden of the disease due to their unique circumstances, whether at home, at work or in their communities, which can affect them from diagnosis through treatment and beyond.
  • Impact on emotional and mental health: A person diagnosed with cancer is twice as likely to experience mental health problems compared to a person without the disease. These impacts can be even greater for individuals diagnosed as a young adult and can persist long after treatment ends.
  • Relationships afterward: Cancer touches all those who care about the person living with the disease. It deeply affects friends and family on emotional and physical levels as they do their best to support their loved one over time.

"Living long-term with cancer is a relatively new idea. We've made tremendous progress in addressing the disease itself, but we still need to answer the question of what comes next, outside of treatment," said Adam Lenkowsky, Head of U.S. Oncology, Bristol-Myers Squibb. "By bringing cancer survivorship into greater focus with this series, our goal is to help start a dialogue on the realities of living with cancer, so we can work together toward a day when all people with cancer can live longer, healthier lives and get the support they need."

Watch the series at SurvivorshipToday.com.

About Survivorship Today

Survivorship Today: What It's Like to Live with Cancer is an initiative by Bristol-Myers Squibb that, through the stories of people living with cancer, aims to advance our understanding of what it's like to live with the disease today and inspire action to provide better support.

About Cancer Survivorship

Cancer survivorship refers to the time from diagnosis throughout the remainder of a person’s life. There are nearly 17 million cancer survivors in the U.S. today. Over the next 10 years, this number is projected to increase to nearly 22 million. Today, more than 67 percent of people living with cancer have been alive for at least five years after their initial diagnosis, and more than 45 percent of people have been alive 10 years after diagnosis. However, many people living with cancer feel unprepared for life after active treatment.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...